Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alglucosidase alfa - Sanofi

X
Drug Profile

Alglucosidase alfa - Sanofi

Alternative Names: Alglucosidase alpha; GZ419829; human acid alpha-glucosidase; Lumizyme; Myozyme; Pompase; recombinant human acid alpha-glucosidase; rhGAA

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi
  • Class Alpha-glucosidases; Recombinant proteins
  • Mechanism of Action Alpha-glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glycogen storage disease type II

Most Recent Events

  • 22 Apr 2017 Long term efficacy pooled data from a phase III and phase IV trial in Glycogen-storage-disease-type-II presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 01 Aug 2014 US FDA approves sBLA for alglucosidase alfa (Lumizyme®) for patients of any age or phenotype with Glycogen storage disease type II in USA
  • 02 Sep 2013 Genzyme initiates enrolment in the phase IV PAPAYA trial for Pompe's disease in US, Germany, India, Russia and Ukraine (NCT01410890)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top